Comparison of neuroendocrine dysfunction in patients with adamantinomatous and papillary craniopharyngiomas

Feng,Ying; Ni,Ming; Wang,Yong‑Gang; Zhong,Li‑Yong

doi:10.3892/etm.2018.6953

Comparison of neuroendocrine dysfunction in patients with adamantinomatous and papillary craniopharyngiomas

Authors:
- Ying Feng
- Ming Ni
- Yong‑Gang Wang
- Li‑Yong Zhong
View Affiliations

Affiliations: Department of Endocrinology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, P.R. China, Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, P.R. China
Published online on: November 12, 2018 https://doi.org/10.3892/etm.2018.6953
Pages: 51-56
Copyright: © Feng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Craniopharyngiomas (CPs) are rare epithelial tumors mainly located in the sellar/parasellar region. They may be classified into two major histological subtypes, which exhibit clinical and pathological differences: Adamantinomatous CP (ACP) and papillary CP (PCP). The aim of the present study was to compare the neuroendocrine dysfunction between ACP and PCP prior to and after surgical resection. According to their pathological classification, the patients were assigned to the ACP group or the PCP group. The neuroendocrine dysfunction in these two CP subtypes was evaluated using a scoring method prior to and after surgery. A total of 741 patients with CPs were included in the present study, of which 622 were ACP and 119 were PCP. The scores on the tumor mass effect, hypothalamic dysfunction and pituitary‑target gland axis dysfunction, as well as the incidence of central diabetes insipidus in the PCP group were all significantly higher than those in the ACP group, regardless of whether the surgery had been performed or not (all P<0.05). After surgery, the scores on the tumor mass effect were significantly decreased in the ACP and PCP patients (all P<0.05), while the scores on hypothalamic dysfunction and pituitary‑target gland axis dysfunction, as well as the incidence of central diabetes insipidus were all significantly increased in ACP and PCP patients (all P<0.05). Prior to and after surgery, the PCP variant exhibited a greater damage to the neuroendocrine function compared with the ACP variant.

View Figures

View References

1	Elliott RE and Wisoff JH: Surgical management of giant pediatric craniopharyngiomas. J Neurosurg Pediatr. 6:403–416. 2010. View Article : Google Scholar : PubMed/NCBI
2	Poretti A, Grotzer MA, Ribi K, Schonle E and Boltshauser E: Outcome of craniopharyngioma in children: Long-term complications and quality of life. Dev Med Child Neurol. 46:220–229. 2004. View Article : Google Scholar : PubMed/NCBI
3	Qi ST, Zhou J, Pan J, Zhang C, Silky C and Yan XR: Epithelial-mesenchymal transition and clinicopathological correlation in craniopharyngioma. Histopathology. 61:711–725. 2012. View Article : Google Scholar : PubMed/NCBI
4	Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
5	Aquilina K, Merchant TE, Rodriguez-Galindo C, Ellison DW, Sanford RA and Boop FA: Malignant transformation of irradiated craniopharyngioma in children: Report of 2 cases. J Neurosurg Pediatr. 5:155–161. 2010. View Article : Google Scholar : PubMed/NCBI
6	Daubenbuchel AM and Muller HL: Neuroendocrine disorders in pediatric craniopharyngioma patients. J Clin Med. 4:389–413. 2015. View Article : Google Scholar : PubMed/NCBI
7	Balcazar-Hernandez L, Vargas-Ortega G, Valverde-Garcia Y, Mendoza-Zubieta V and Gonzalez-Virla B: Anorexia-cachexia syndrome-like hypothalamic neuroendocrine dysfunction in a patient with a papillary craniopharyngioma. Endocrinol Diabetes Metab Case Rep 2017. 2017. View Article : Google Scholar
8	Caldarelli M, Massimi L, Tamburrini G, Cappa M and Di Rocco C: Long-term results of the surgical treatment of craniopharyngioma: The experience at the Policlinico Gemelli, Catholic University, Rome. Childs Nerv Syst. 21:747–757. 2005. View Article : Google Scholar : PubMed/NCBI
9	Nielsen EH, Feldt-Rasmussen U, Poulsgaard L, Kristensen LO, Astrup J, Jørgensen JO, Bjerre P, Andersen M, Andersen C, Jørgensen J, et al: Incidence of craniopharyngioma in Denmark (n=189) and estimated world incidence of craniopharyngioma in children and adults. J Neurooncol. 104:755–763. 2011. View Article : Google Scholar : PubMed/NCBI
10	Karavitaki N: Management of craniopharyngiomas. J Endocrinol Invest. 37:219–228. 2014. View Article : Google Scholar : PubMed/NCBI
11	Lubuulwa J and Lei T: Pathological and topographical classification of craniopharyngiomas: A literature review. J Neurol Surg Rep. 77:e121–e127. 2016. View Article : Google Scholar : PubMed/NCBI
12	Holsken A, Sill M, Merkle J, Schweizer L, Buchfelder M, Flitsch J, Fahlbusch R, Metzler M, Kool M, Pfister SM, et al: Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles. Acta Neuropathol Commun. 4:202016. View Article : Google Scholar : PubMed/NCBI
13	Martinez-Barbera JP: Molecular and cellular pathogenesis of adamantinomatous craniopharyngioma. Neuropathol Appl Neurobiol. 41:721–732. 2015. View Article : Google Scholar : PubMed/NCBI
14	Martinez-Barbera JP and Buslei R: Adamantinomatous craniopharyngioma: Pathology, molecular genetics and mouse models. J Pediatr Endocrinol Metab. 28:7–17. 2015. View Article : Google Scholar : PubMed/NCBI
15	Brastianos PK and Santagata S: ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma. Eur J Endocrinol. 174:R139–R144. 2016. View Article : Google Scholar : PubMed/NCBI
16	Brastianos PK, Taylor-Weiner A, Manley PE, Jones RT, Dias-Santagata D, Thorner AR, Lawrence MS, Rodriguez FJ, Bernardo LA, Schubert L, et al: Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet. 46:161–165. 2014. View Article : Google Scholar : PubMed/NCBI
17	Szeifert GT, Sipos L, Horvath M, Sarker MH, Major O, Salomváry B, Czirják S, Bálint K, Slowik F, Kolonics L, et al: Pathological characteristics of surgically removed craniopharyngiomas: Analysis of 131 cases. Acta Neurochir (Wien). 124:139–143. 1993. View Article : Google Scholar : PubMed/NCBI
18	Muller HL: Craniopharyngioma: Long-term consequences of a chronic disease. Expert Rev Neurother. 15:1241–1244. 2015. View Article : Google Scholar : PubMed/NCBI
19	Lopez-Serna R, Gomez-Amador JL, Barges-Coll J, Nathal-Vera E, Revuelta-Gutiérrez R, Alonso-Vanegas M, Ramos-Peek M and Portocarrero-Ortiz L: Treatment of craniopharyngioma in adults: Systematic analysis of a 25-year experience. Arch Med Res. 43:347–355. 2012. View Article : Google Scholar : PubMed/NCBI
20	Esheba GE and Hassan AA: Comparative immunohistochemical expression of β-catenin, EGFR, ErbB2, and p63 in adamantinomatous and papillary craniopharyngiomas. J Egypt Natl Canc Inst. 27:139–145. 2015. View Article : Google Scholar : PubMed/NCBI
21	Puget S, Garnett M, Wray A, Grill J, Habrand JL, Bodaert N, Zerah M, Bezerra M, Renier D, Pierre-Kahn A and Sainte-Rose C: Pediatric craniopharyngiomas: Classification and treatment according to the degree of hypothalamic involvement. J Neurosurg. 106:3–12. 2007.PubMed/NCBI
22	Bunin GR, Surawicz TS, Witman PA, Prestonmartin S, Davis F and Bruner JM: The descriptive epidemiology of craniopharyngioma. J Neurosurg. 89:547–551. 1998. View Article : Google Scholar : PubMed/NCBI
23	Sorva R and Heiskanen O: Craniopharyngioma in Finland. A study of 123 cases. Acta Neurochir (Wien). 81:85–89. 1986. View Article : Google Scholar : PubMed/NCBI
24	Müller HL: Consequences of craniopharyngioma surgery in children. J Clin Endocrinol Metab. 96:1981–1991. 2011. View Article : Google Scholar : PubMed/NCBI
25	Muller HL: Craniopharyngioma and hypothalamic injury: Latest insights into consequent eating disorders and obesity. Curr Opin Endocrinol Diabetes Obes. 23:81–89. 2016. View Article : Google Scholar : PubMed/NCBI
26	Scarfone RJ, Loiselle JM, Wiley JF II, Decker JM, Henretig FM and Joffe MD: Nebulized dexamethasone versus oral prednisone in the emergency treatment of asthmatic children. Ann Emerg Med. 26:480–486. 1995. View Article : Google Scholar : PubMed/NCBI